Therapeutic Solutions International Inc (TSOI)

[centsability4me]

TSOI most recent CTE PR
10/25/18
http://ih.advfn.com/p.php?pid=nmona&article=78538984

TSOI new formulation
the CTE trail - where it crosses the Blood-Brain Barrier.

Therapeutic Solutions International Announces CTE Optimized NeuroStilbene Formulation


OCEANSIDE, CA -- October 25, 2018 -- InvestorsHub NewsWire -- Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today a newly optimized formulation of NeuroStilbene for intranasal delivery. The company has previously filed intellectual property and generated data demonstrating suppression of neuronal cell death and reduction of neuroinflammation in models of Chronic Traumatic Encephalopathy (CTE). The optimized formulation developed, possesses an enhanced delivery ability and increased concentration of the active ingredient, pterostilbene.

Chronic Traumatic Encephalopathy (CTE) is a progressive degenerative disease of the brain found in people with a history of repetitive brain trauma such as athletes and military veterans. The trauma may include symptomatic concussions as well as asymptomatic sub-concussive hits to the head that do not cause symptoms. Common symptoms of CTE in the early stages of the condition include impulse control problems, aggression, depression, and paranoia. As the disease progresses, some patients may experience problems with thinking and memory, including memory loss, confusion, impaired judgment, and eventually progresses to dementia.

"In an ideal setting, clinical implementation of NeuroStilbene requires delivery of the highest amount of pterostilbene possible in the most effective manner," said Dr. James Veltmeyer, Chief Medical Officer of Therapeutic Solutions International. "The new formulation utilizes nanoparticle technology, combined with proprietary chemistry to ensure optimal concentrations of the active agent are found in the central nervous system to prevent pathology associated with neuronal injury."

"The newly formulated NeuroStilbene is 6.6x more concentrated than our previous version which contained 30mg of nanoparticle pterostilbene per milliliter of the nanoemulsion. This new formulation contains 200mg per milliliter. This means we can deliver six times more pterostilbene intranasally per application than current formulation that is now increased from 3mg to 20mg per pump application" said Timothy Dixon, President, and CEO of TSOI. "We are eager to start receiving feedback from our collaborators on the effects of this new formulation".